Musolino A; Michiara M; Conti GM; Boggiani D; Bozzani F; Zatelli M; Sgargi P; Ardizzoni A, HER2 STATUS AS PREDICTOR OF MAMMOGRAPHIC SCREENING DETECTION: COMPARISON OF INTERVAL- AND SCREEN-DETECTED BREAST CANCERS, «ANNALS OF ONCOLOGY», 2010, 21, pp. 78 - 79 [replica/breve intervento]
Bozzetti C; Tiseo M; Lagrasta C; Nizzoli R; Guazzi A; Graiani G; Rindi G; Ardizzoni A, Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non-small Cell Lung Cancer?, «JOURNAL OF THORACIC ONCOLOGY», 2010, 5, pp. 551 - 553 [replica/breve intervento]
Gridelli C; Ardizzoni A; Bajetta E; Barni S; Crino L; Caprioli A; Filipazzi V; Lorusso V; De Marinis F, MEDICAL TREATMENT CHOICES OF PATIENTS AFFECTED BY ADVANCED NSCLC IN ROUTINE CLINICAL PRACTICE: RESULTS FROM THE ITALIAN OBSERVATIONAL "SUN'' (SURVEY ON THE LUNG CANCER MANAGEMENT) STUDY, «ANNALS OF ONCOLOGY», 2010, 21, pp. 151 - 151 [abstract]
Carmi C.; Cavazzoni A.; Vezzosi S.; Bordi F.; Vacondio F.; Silva C.; Rivara S.; Lodola A.; Alfieri R.; Monica S. La; Galetti M.; Ardizzoni A.; Petronini P.G.; Mor M., Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion, «JOURNAL OF MEDICINAL CHEMISTRY», 2010, 53, pp. 2038 - 2050 [replica/breve intervento]
Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A, Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers, «LUNG CANCER», 2010, 67, pp. 355 - 360 [replica/breve intervento]
F.NEGRI; C. BOZZETTI; CA. LAGRASTA; P. CRAFA; MP. BONASONI; R. CAMISA; G. PEDRAZZI; ARDIZZONI A, PTEN status in advanced colorectal cancer treated with cetuximab, «BRITISH JOURNAL OF CANCER», 2010, 102, pp. 162 - 164 [replica/breve intervento]
Gridelli C; Ardizzoni A; Douillard JY; Hanna N; Manegold C; Perrone F; Pirker R; Rosell R; Shepherd FA; De Petris L; Di Maio M; de Marinis F, Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology, «LUNG CANCER», 2010, 68, pp. 319 - 331 [replica/breve intervento]
Ardizzoni A; Boni L; Tiseo M; Marini L; Mehmud F, REFRACTORY VS SENSITIVE RELAPSED SCLC: VALIDATION OF STANDARD DEFINITION AND ASSESMENT OF ALTERNATIVE CLASSIFICATION, «ANNALS OF ONCOLOGY», 2010, 21, pp. 148 - 148 [abstract]
Tiseo M; Gridelli C; Cascinu S; Crino L; Piantedosi FV; Grossi F; Brandes AA; Labianca R; Siena S; Amoroso D; Belvedere O; Valentino B; Bearz A; Venturino P; Ardizzoni A, An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy, «LUNG CANCER», 2009, 64, pp. 199 - 206 [replica/breve intervento]
Tibaldi C; Giovannetti E; Tiseo M; Danesi R; Leon LG; Bartolotti M; D'Incecco A; Erozenci AL; Falcone A; Peters GJ; Ardizzoni A, Correlation between cytidine deaminase (CDA) genotype and clinical outcome/toxicity in advanced non-small cell lung cancer (NSCLC) patients treated with gemcitabine/platinum-based chemotherapy, «JOURNAL OF THORACIC ONCOLOGY», 2009, 4, pp. S553 - S553 [abstract]
Tiseo M; Bordi P; Bortesi B; Azzoni C; Campanini N; Boni L; Boni C; Baldini E; Grossi F; Recchia F; Zanelli F; Fontanini G; Naldi N; Rindi G; Bordi C; Ardizzoni A, ERCC 1/BRCA1 PROTEIN EXPRESSIONS AND ERCC1/XPD/XRCC1-3 GENE POLYMORPHISMS AS PREDICTOR FACTORS OF OUTCOME IN STAGE IIIB-IV NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED IN FIRST-LINE CHEMOTHERAPY WITH OR WITHOUT CISPLATIN, «ANNALS OF ONCOLOGY», 2009, 20, pp. 1695 - 1703 [abstract]
Tiseo M; Bordi P; Bortesi B; Boni L; Boni C; Baldini E; Grossi F; Recchia F; Zanelli F; Fontanini G; Naldi N; Bordi C; Ardizzoni A, ERCC 1/BRCA1 protein expressions and ERCC1/XPD/XRCC1-3 gene polymorphisms as predictor factors of outcome in stage III-IV non-small cell lung cancer (NSCLC) patients treated in first-line chemotherapy with or without cisplatin, «JOURNAL OF THORACIC ONCOLOGY», 2009, 4, pp. S402 - S402 [abstract]
La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Ardizzoni A; Tiseo M; Capelletti M; Goldoni M; Tagliaferri S; Mutti A; Fumarola C; Bonelli M; Generali D; Petronini PG, Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines, «BIOCHEMICAL PHARMACOLOGY», 2009, 78, pp. 460 - 468 [replica/breve intervento]
M. Tiseo; M. Bartolotti; F. Gelsomino; Ardizzoni A, First LineTreatment in advanced non small-cell lung cancer: the emerging role of the histologic subtype, «EXPERT REVIEW OF ANTICANCER THERAPY», 2009, 9, pp. 425 - 435 [replica/breve intervento]
Gridelli C; Bajetta E; De Marinis F; Crino L; Barni S; Ardizzoni A; Gebbia V; Adamo V; Morena R; Caprioli A, First-line treatment of over 1000 Italian patients affected by stage IIIB-IV NSCLC: results from the observational "Sun" (Survey on the Lung Cancer Management) study, «JOURNAL OF THORACIC ONCOLOGY», 2009, 4, pp. S453 - S453 [abstract]
